127 research outputs found
Script underlying the paper "On Robustly Convergent and Efficient Iterative Methods for Anisotropic Radiative Transfer"
No full text*** Solver for anisotropic radiative transfer in an XY-geometry ***
authors: J. Dölz, O. Palii, M. Schlottbom
corresponding author: Matthias Schlottbom, University of Twente, [email protected]
*** Scientific reference ***
Jürgen Dölz, Olena Palii, Matthias Schlottbom
On robustly convergent and efficient iterative methods for anisotropic radiative transfer.
Journal of Scientific Computing 90 (94), 2022.
https://doi.org/10.1007/s10915-021-01757-9
When using this code, cite that paper.
*** Description ***
For using the code, unzip the repository and run solve.m.
In lines 4-12, there are parameters regarding the solver and meshes used.
In line 51, a function is called that specifies the optical parameters.</p
The research of antibacterial properties of decamethoxin, decasan, horosten
No full textPalii H. K., Dudar A. O., Pavliuk S. V., Nazarchuk O. A., Palii D. V., Kulyk A. V. The research of antibacterial properties of decamethoxin, decasan, horosten. Journal of Education, Health and Sport. 2019;9(10):94-102. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.3483760
http://ojs.ukw.edu.pl/index.php/johs/article/view/7580
The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017).
1223 Journal of Education, Health and Sport eISSN 2391-8306 7
© The Authors 2019;
This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.
(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 03.10.2019. Revised: 08.10.2019. Accepted: 14.10.2019.
UDC: 615.281
The research of antibacterial properties of decamethoxin, decasan, horosten
H. K. Palii, A. O. Dudar, S. V. Pavliuk, O. A. Nazarchuk, D. V Palii, A. V. Kulyk
National Pirogov Memorial Medical University, Vinnytsya,
Ministry of Public Health of Ukraine,
Department of Microbiology, Virology and Immunology
Abstract
The study of Staphylococcus resistance to the antibacterial drugs Decamethoxin, Decasan, Horosten remains an important medical problem.
The aim of this study was to investigate the antistaphylococcal properties of Decamethoxin, Decasan, Horosten. It has been proven that qaterinary ammonium antiseptic drugs (Decamethoxin, Decasan, Horosten) have high antistaphylococcal properties. The bactericidal activity of Decamethoxin has been shown to be stable under adverse pH conditions of different microbial loading. Different concentrations of Decamethoxine have been shown to cause the formation of resistant variants of Staphylococcus, which lose the ability to form pigments and enzymes.
Key words: Staphylococci, antiseptics, properties, decamethoxin, decasan, horosten, resistance
Script underlying the paper "On Robustly Convergent and Efficient Iterative Methods for Anisotropic Radiative Transfer"
No full text*** Solver for anisotropic radiative transfer in an XY-geometry ***
authors: J. Dölz, O. Palii, M. Schlottbom
corresponding author: Matthias Schlottbom, University of Twente, [email protected]
*** Scientific reference ***
Jürgen Dölz, Olena Palii, Matthias Schlottbom
On robustly convergent and efficient iterative methods for anisotropic radiative transfer.
Journal of Scientific Computing 90 (94), 2022.
https://doi.org/10.1007/s10915-021-01757-9
When using this code, cite that paper.
*** Description ***
For using the code, unzip the repository and run solve.m.
In lines 4-12, there are parameters regarding the solver and meshes used.
In line 51, a function is called that specifies the optical parameters.</p
Script underlying the paper "On Robustly Convergent and Efficient Iterative Methods for Anisotropic Radiative Transfer"
No full text*** Solver for anisotropic radiative transfer in an XY-geometry ***
authors: J. Dölz, O. Palii, M. Schlottbom
corresponding author: Matthias Schlottbom, University of Twente, [email protected]
*** Scientific reference ***
Jürgen Dölz, Olena Palii, Matthias Schlottbom
On robustly convergent and efficient iterative methods for anisotropic radiative transfer.
Journal of Scientific Computing 90 (94), 2022.
https://doi.org/10.1007/s10915-021-01757-9
When using this code, cite that paper.
*** Description ***
For using the code, unzip the repository and run solve.m.
In lines 4-12, there are parameters regarding the solver and meshes used.
In line 51, a function is called that specifies the optical parameters.</p
Markerii stresului oxidativ în insuficienţa cardiacă pediatric secundară cardiopatiilor congenitale asociate cu hipertensiune pulmonară
No full textStudiul dat a cuprins 94 de copii cu ICC secundară cardiopatiilor congenitale, la care s-au determinat nivele serice ale unor indici ai stresului oxidativ în serul sangvin:
hidroperoxizii lipidici (HPL) timpurii, intermediari şi tardivi, dialdehida malonică (DAM) şi activitatea antioxidantă totală (AAT). Lotul I, de bază, l-au constituit 75 de bolnavi cu ICC şi HTPA de diferit grad, şi lotul II, de comparaţie – 19 pacienţi cu ICC, dar fără HTPA. Rezultatele obţinute au fost comparate cu lotul de sănătoşi – 20 de
copii cu vârste similare. S-au depistat valori serice crescute ale HPL, DAM la pacienţii cu ICC secundară şunturilor congenitale complicate cu HTPA, faţă de lotul-martor, dar
mai pergnant la cei cu HTPA severă, depăşind nivelul copiilor cu HTPA moderată (
Notă de referinţă asupra monografiei „Hipertensiunea arterială esenţială la copii” autorul monografiei: Nelea Mătrăgună, doctor în medicină, conferenţiar, Şef Laborator Cardiologie Pediatrică
No full textСиндром сердечной недостаточности у детей (стандартизированный клинический протокол для отделений неотложной помощи)
No full textIMSP Institutul Mamei şi Copilului, Universitatea de Stat de Medicină şi Farmacie “Nicolae Testemiţanu”,
Departamentul PediatrieIntroduction: Heart failure (HF) syndrome is defined by the heart’s inability to produce cardiac output systemic or
pulmonary for tissue needs or to support it under increased filling pressures.
Aim: Studying Heart Failure Syndrome management in Children.
Materials and Methods: The article is based on medical publications from international literature and online
material.
Results: HR causes are divided into cardiac and extracardiac. The cardiac causes are structural abnormalities -
cardiac overload, left-right shunt, pressure overload, valvular insufficiency, but may also be “normal” in the regular
heart - primary and secondary cardiomyopathy. Typical clinical manifestations in children may be tachypnea, alimentation
problems (reflux, vomiting, loss of appetite), diaphoresis, and palpitations. The paraclinical evaluation includes
routine analyzes and NT-proBNP, BNP, CK, MB fractions, cardiac troponins, C-reactive protein, and functional and
interventional tests (ECG standard 12 derivates, thoracic radiography + ICT, Echocardiography, Doppler-EcoCG).
Treatment of acute HF includes diuretics, inotropic therapy - milrinone, dobutamine, epinephrine, digoxin, systemic
vasodilators. Chronic HF therapy includes IECA (captopril, enalapril, ramipril, perindopril), angiotensin II receptor
antagonists - losartan, beta-blockers, aldosterone antagonists.
Conclusion: The key to achieving therapeutic success and implicitly the survival of the pediatric patient is the appreciation
and treatment of the HF cause and gradual introduction of drug therapy according to the severity of clinical
and paraclinical data.Введение. Синдром сердечной недостаточности (СН) определяется неспособностью сердца обеспечить
системный или легочной систолический объем крови в соответствии с тканевыми потребностями, а также
поддерживания этого объема при повышенном давлении наполнения.
Цель. Изучение принципов неотложной помощи при синдроме сердечной недостаточности у детей.
Материалы и методы. Статья основана на современных данных опубликованных в медицинских изданиях,
международной литературе и онлайн-материалах.
Результаты. Причины СН делятся на сердечные и внесердечные. Сердечные причины это структурные
аномалии развития – пороки сердца которые приводят к сердечной перегрузке объемом, с лево-правым направлением сброса, с перегрузкой давлением, клапанная недостаточность, но также могут быть при нормально
развитом сердце – первичные и вторичные кардиомиопатии. Типичными клиническими проявлениями у ново-
рожденных и детей грудного возраста могут быть учащенное дыхание, проблемы с питанием (срыгивания,
рвота, потеря аппетита), потоотделение, бледность. Параклиническое обследование включает в себя рутинные анализы, а также фракции NT-proBNP, BNP, CK, фракция MB, сердечные тропонины, C-реактивный белок
и функциональные и интервенционные тесты (стандартное ЭКГ, рентгенография органы грудной клетки +
измерение КТИ, эхокардиография, ЭХО-КГ сердца с допплерометрией). Лечение острой СН включает петле-
вые диуретики, инотропную терапию (недостаточно доказательств), милринон, добутамин, адреналин, дигоксин, системные вазодилататоры. Лечение хронической СН включает ингибиторы АПФ (каптоприл, эналаприл, рамиприл, периндоприл), антагонисты рецепторов ангиотензина II - лозартан, бета-блокаторы (метопролол, бисопролол, карведилол), антагонисты альдостерона.
Вывод. Ключевым фактором достижения терапевтического успеха и увеличения продолжительности
жизни больного ребёнка является выявление и лечение причины сердечной недостаточности, а также поэтапное введение лекарственной терапии в зависимости от тяжести клинических и параклинических данных
UP-to-dateness in the treatment of heart failure in children with congenital heart disease and systemic pulmonary shunt
No full textClinica de cardiologie pediatrică ICŞDOSMC USMF „Nicolae Testemiţanu”,
Laboratorul de Insuficienţă Cardiacă, Institutul de CardiologieConsidering heart failure secondary CHD in children a nowadays problem, of major health in the meaning of diagnosis and treatment, in this study it has been evaluated the efficacy and the tolerability of highly specific phosphodiesterase 5 inhibitor in the children’s long treatment with HF associated with PH caused by congenital systemic-to-pulmonary shunts. The study results have been proved that Sildenafil – a pulmonary vasodilator is an efficient preparation in HF associated with PH secondary CHD, improving FC (P<0,01), tolerability at effort (P<0,001), systemic O2 saturation (P<0,05), diminishing PAPm (P<0,001) and PVRI in comparison with placebo. In baby till 1 year, Sildenafil is tipically initiated at a dose of 0,5mg/kg, but in big child – the recommendated dose is 1 mg/kg, then 1 and 2 mg/kg every day, every 6 hours shows a good tolerability at this preparation, with small and unimportant reactions, forestalling the severe complications and having a benefit impact on the quality life of this children.
Considerând insuficienţa cardiacă (IC) secundară malformaţiilor cardiace congenitale (MCC) la copii o problemă majoră de sănătate, în acest studiu a fost evaluată eficacitatea şi tolerabilitatea pe termen lung a inhibitorului selectiv al fosfodiesterazei 5 la copiii cu IC şi hipertensiune pulmonară (HTP) cauzată de şunturi sistemico-pulmonare. Rezultatele studiului au demonstrat că Sildenafilul - vasodilatator pulmonar este un preparat efectiv în IC asociată cu HTP secundară MCC, îmbunătăţind CF (P<0,01), tolerabilitatea la efort (P<0,001), saturaţia O2 sistemică (P<0,05), funcţia sistolică a VD (P<0,05), diminuează PAPm (P<0,001) şi IRVP în comparaţie cu placebo. La copiii sugari doza iniţială este de 0,5mg/kg, urmată de 1 mg/kg la o tolerabilitate bună, iar la copiii mai mari, respectiv 1 şi 2 mg/kg zilnic fiecare 6 ore. Preparatul a demonstrat o tolerabilitate bună cu reacţii adverse minore şi neînsemnate, previne complicaţiile severe şi are un impact benefic asupra calităţii vieţii acestor copii
Metabolic syndrome in children: cardiovascular consequences
No full textNicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova, Department of Pediatrics, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltar
- …
